Smith & Nephew SNATS, Inc. $SNN Shares Acquired by Todd Asset Management LLC

Todd Asset Management LLC lifted its stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 30.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 944,578 shares of the medical equipment provider’s stock after buying an additional 219,348 shares during the quarter. Todd Asset Management LLC owned approximately 0.22% of Smith & Nephew SNATS worth $30,992,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Paradigm Asset Management Co. LLC acquired a new position in shares of Smith & Nephew SNATS during the third quarter worth about $1,502,000. Citigroup Inc. grew its position in shares of Smith & Nephew SNATS by 44.8% during the third quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider’s stock worth $17,661,000 after buying an additional 150,517 shares in the last quarter. Factory Mutual Insurance Co. acquired a new position in shares of Smith & Nephew SNATS during the third quarter worth about $1,007,000. Teachers Retirement System of The State of Kentucky acquired a new position in shares of Smith & Nephew SNATS during the third quarter worth about $16,501,000. Finally, Perpetual Ltd acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter worth about $1,518,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Down 0.1%

Shares of NYSE SNN opened at $30.51 on Monday. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a twelve month low of $28.33 and a twelve month high of $38.79. The stock has a 50 day moving average of $31.91 and a two-hundred day moving average of $33.16.

Smith & Nephew SNATS (NYSE:SNN) last issued its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The firm had revenue of $1.60 billion during the quarter. On average, research analysts expect that Smith & Nephew SNATS, Inc. will post 2.25 EPS for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be paid a $0.482 dividend. The ex-dividend date is Friday, March 27th. This represents a yield of 304.0%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SNN shares. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday. Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a research note on Monday, May 11th. Wall Street Zen cut Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group decreased their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Smith & Nephew SNATS currently has a consensus rating of “Moderate Buy” and an average target price of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.